期刊文献+

PTEN基因逆转卵巢上皮性癌细胞耐药的机制研究 被引量:8

Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms
原文传递
导出
摘要 目的通过检测 PTEN 基因在卵巢上皮性癌(卵巢癌)顺铂敏感细胞株 OV2008及OV2008配对的顺铂耐药细胞株 C13K 中的表达,探讨转染 PTEN 基因能否逆转 C13K 细胞对顺铂的耐药及其相关机制。方法半定量 RT-PCR 技术和蛋白印迹法检测 OV2008和 C13K 细胞中 PTENmRNA 和蛋白的表达。将野生型 PTEN 基因真核表达质粒在脂质体介导下转染 C13K 细胞,同时以转染空载体和未转染的 C13K 细胞作为对照,分别应用 RT-PCR 技术检测各组细胞 PTEN mRNA 表达的变化,应用蛋白印迹法检测各组细胞 PTEN、蛋白激酶 B(AKT)及磷酸化 AKT(p-AKT)蛋白表达的变化;四甲基偶氮唑蓝(MTT)比色法观察转染 VFEN 基因后 C13K 细胞对顺铂敏感性的变化,流式细胞仪分析顺铂作用后的细胞凋亡情况。结果 (1)PTEN mRNA 在 OV2008和 C13K 细胞中的表达水平分别为1.02±0.05和0.45±0.03,而 OV2008、C13K 细胞中 PTEN 蛋白的表达水平分别为1.02±0.07、0.55±0.03,两种细胞 PTEN mRNA 和蛋白的表达水平分别比较,差异均有统计学意义(P<0.05)。(2)PTEN 基因转染48 h 后,C13K 细胞中 PTEN mRNA、蛋白的表达水平分别为2.04±0.10和0.94±0.04,分别与转染空载体和未转染的 C13K 细胞比较,差异均有统计学意义(P<0.01);p-AKT 蛋白的表达水平(0.94±0.07)较转染空载体(1.66±0.10)和未转染(1.68±0.14)的 C13K 细胞显著降低(P<0.05)。(3)转染 PTEN 基因的 C13K 细胞对顺铂的半数抑制浓度(IC_(50))为(7.2±0.3)μmol/L,明显高于转染空载体和未转染的 C13K 细胞[分别为(12.7±0.4)、(13.0±0.3)μmo]/L,P<0.05]。(4)顺铂作用24 h 后,转染 PTEN 基因、转染空载体和未转染的 C13K 细胞的凋亡率分别为(41.7±0.9)%、(18.6±0.7)%和(15.3±0.8)%,前者明显高于后两者(P<0.01)。结论 PTEN 基因在 OV2008细胞中的表达明显高于 C13K 细胞。转染野生型 PTEN 基因能有效提高C13K 细胞内 PTEN 基因的表达,并通过降低 C13K 细胞中 AKT 磷酸化的水平恢复 C13K 细胞对顺铂的敏感性。 Objective To examine expression of PTEN gene in ovarian cancer cisplatin-sensitive cell line OV2008 cells and cisplatin-resistant cell line C13K cells, and evaluate the effect of wild-type PTEN gene on reversing cisplatin-resistance of C13K cells and underlying mechanisms. Methods The expression of PTEN mRNA and protein in OV2008 and C13K cells were detected by semi-quantitative RT-PCR and western blot. Recombinant eukaryotic expression plasmid containing human wild-type PTEN gene was transfected into C13K cells by lipofectamine 2000. The expression of PTEN mRNA was monitored by RTPCR and the expression of PTEN, protein kinase B (AKT) , phospho-AKT (p-AKT) protein were analyzed by western blot in PTEN transfected and untransfected C13K cells. Proliferation and chemosensitivity of cells to cisplatin were measured by methyl thiazolyl tetrazolium ( MTT), and cell apoptosis was detected by flow cytometry after treatment with cisplatin. Results ( 1 ) The expression of PTEN mRNA and protein ( 1.02 ± 0. 05, 1.02 ± 0. 07 ) in OV2008 cells were significantly higher than those in C13 K cells, which were 0. 45 ±0. 03 and 0. 55 ±0. 03 respectively (P 〈0. 05). (2) After transfected with PTEN gene for 48 hours, the expression of PTEN mRNA and protein in CI3K cells were 2.04 ± 0. 10, 0.94 ± 0.04 respectively. Compared with C13K cells transfected with empty vector (1.04 ± 0. 04, 0. 36 ± 0. 03 ) and untransfected CI3K cells ( 1.03 ± 0. 05, 0. 37 ± 0. 03 ), the difference was significant respectively ( P 〈 0. 01 ). The expression of p-AKT protein (0. 94 ±0.07) was lower than those in control groups ( 1.66 ±0. 10, 1.68 ±0. 14; P 〈0. 05). (3) The 50% inhibition concentration ( IC50 ) to cisplatin of CI3K cells transfected with PTEN [ (7.2 ± 0. 3 ) μmol/L] was obviously lower than those of empty-vector transfected cells and untransfected cells [ ( 12.7 ± 0. 4), ( 13.0 ± 0. 3 ) Ixmol/L; P 〈 0. 05 ]. (4) The apoptosis ratio of C 13 K cells with wild-type PTEN transfection, empty vector transfection and untransfected were (41.7 ±0. 9)%, ( 18. 6 ± 0. 7 ) % and ( 15.3 ± 0. 8 ) % respectively ( P 〈 0. 01 ). Conclusions PTEN gene plays an important role in ovarian cancer multidrug resistance. Transfection of PTEN could increase the expression of PTEN and restore drug sensitivity to cisplatin in muhidrug-resistant human ovarian cancer cell line C13K by decreasing the expression of p-AKT.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2007年第9期612-616,共5页 Chinese Journal of Obstetrics and Gynecology
基金 国家自然科学基金(30571950) 国家重点基础研究发展计划(2002CB513107)
关键词 卵巢肿瘤 PTEN磷酸水解酶类 顺铂 抗药性 肿瘤 Ovarian neoplasms PTEN phosphohydrolase Cisplatin Drug resistance, neoplasm
  • 相关文献

参考文献13

  • 1Sehondorf T, Becker M, Gohring UJ, et al. Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN. Anticancer Drugs,2001,12 : 797-780.
  • 2Tamura M, Gu J, Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion, migration and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res, 1999,59 : 442-449.
  • 3Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275: 1943-1947.
  • 4Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100:387-390.
  • 5Cantley LC, Neel BG. New insights into tumor suppression : PTEN suppresses tumor formation by restraining the phosphoinositide 3- kinase/AKT pathway. Proc Natl Acad Sci U S A, 1999, 96: 4240-4245.
  • 6Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther,2003,10 : 1636-1642.
  • 7Lee S, Choi EJ, Jin C, et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol, 2005, 97:26-34.
  • 8Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6: 117- 127.
  • 9Zhou M, Gu L, Findley H, et al. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res,2003 ,63 :6357-6362.
  • 10Yan X, Fraser M, Qiu Q, et al. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol, 2006, 102: 348- 355.

同被引文献115

  • 1李敏,于利利,蔡俐琼,汪宏波,王志华,王泽华.bcl-2反义寡核苷酸逆转人卵巢上皮性癌细胞耐药的体外研究[J].中华妇产科杂志,2006,41(2):121-125. 被引量:4
  • 2楼江燕,彭芝兰,郑莹,王和,何斌,王红静.RNA干扰技术逆转卵巢上皮性癌细胞多药耐药的研究[J].中华妇产科杂志,2006,41(6):413-416. 被引量:9
  • 3Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase [J]. Proc Natl Acad Sci U S A, 1997,94(17) : 9052-9057.
  • 4Li J, Yen C, Liow D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J]. Science, 1997, 275(5308): 1943-1947.
  • 5Dahia PL, Aguiar RC, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via muhiple mechanisms in hematological malignancies [ J]. Hum Mol Genet, 1999, 8(2) : 185-193.
  • 6Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts [J]. Genes Dev, 1999, 13(22) : 2905-2927.
  • 7Shen YN, Zhang L, Gan Y, et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling [J]. J Biol Chem, 2006, 281 (12) : 7727-7736.
  • 8Wee KB, Aguda BD. Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death [ J]. Biophys J, 2006, 91 (4): 857-865.
  • 9Vasudevan KM, Gurvmunhy S, Rangnekar VM. Suppression of PTEN expression by NF-kappaB prevents apoptosis [ J]. Mol Cell Biol, 2004, 24(3): 1007-1021.
  • 10Peponi E, Drakos E, Reyes G, et al. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma [ J ]. Am J Pathol, 2006, 169(6) : 2171-2180.

引证文献8

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部